| Dr Jaromir Slama, MD | |
|
725 Albany St, Shapiro 8, Suite A, Boston, MA 02118-2526 | |
| (617) 638-8419 | |
| (617) 414-0201 |
| Full Name | Dr Jaromir Slama |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 28 Years |
| Location | 725 Albany St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518994086 | NPI | - | NPPES |
| 110041761A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 226870 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boston Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boston University General Surgical Associates, Inc. | 9830183763 | 76 |
News Archive
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.
Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 7 days ago
| Entity Name | Boston University General Surgical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104865567 PECOS PAC ID: 9830183763 Enrollment ID: O20040513000398 |
News Archive
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.
Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jaromir Slama, MD 801 Albany St Fl Ground, Boston, MA 02119-2560 Ph: (617) 414-5405 | Dr Jaromir Slama, MD 725 Albany St, Shapiro 8, Suite A, Boston, MA 02118-2526 Ph: (617) 638-8419 |
News Archive
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.
Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 7 days ago
Kevin Cheung, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Stoneman 10, Boston, MA 02215 Phone: 617-632-9839 | |
Jeffrey M Darrow, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 170 Commonwealth Ave, Boston, MA 02116 Phone: 617-267-0710 | |
Daniel S. Roh, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 725 Albany Street, Ste 3a, Shapiro Bldg., Boston, MA 02118 Phone: 617-638-8419 Fax: 617-414-0201 | |
Eugene Yoshio Fukudome, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Wacc 435, Boston, MA 02114 Phone: 617-726-2066 | |
Dr. Thomas C Cochran Jr., MD Plastic Surgery Medicare: Medicare Enrolled Practice Location: 170 Commonwealth Ave, Boston, MA 02116 Phone: 617-267-0710 Fax: 617-236-8704 | |
Dr. Jorge R Lujan Hernandez, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 725 Albany Street, Fl 3 Ste 3, Shapiro Bldg., Boston, MA 02118 Phone: 617-638-8419 Fax: 617-414-0201 | |
Dr. Bernard Travis Lee, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Francis St, Lowry Suite 5a, Boston, MA 02215 Phone: 617-632-7835 |